In an interview with CNBC-TV18, Rajesh Jain, Joint MD, Panacea Biotec says, the company’s earnings before interest, taxes, depreciation, and amortization (EBITDA) margins have grown considerably in Q4. He expects company to grow 25-28% in FY12.
first published: May 13, 2011 05:00 pm
A collection of the most-viewed Moneycontrol videos.
The Tenant Diwali Special: From Mumbai Slums to Alibaug Villas: 2025 Recap
Nifty Snaps 6-Day Winning Streak As Markets Get In Consolidation Mode| Closing Bell Live
Kenneth Andrade picks three unusual, ignored sectors to bet on in Samvat 2082
Nifty Likely To Consolidate Until It Clears 26,000 Mark Decisively | Opening Bell Live
